Related content

Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications

By Pashalidis I.   Kontoghiorghes G.J.  

Transfusion and Apheresis Science, Vol. 23, Iss. 3, 2000-12 ,pp. : 259-261

Elsevier

Access to resources Recommend Favorite

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)

By Berdoukas V.   Bohane T.   Eagle C.   Lindeman R.   DeSilva K.   Tobias V.   Painter D.   Fraser I.  

Transfusion and Apheresis Science, Vol. 23, Iss. 3, 2000-12 ,pp. : 239-240

Elsevier

Access to resources Recommend Favorite

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)

By Kontoghiorghes G.J.   Pattichi K.   Hadjigavriel M.   Kolnagou A.  

Transfusion and Apheresis Science, Vol. 23, Iss. 3, 2000-12 ,pp. : 211-223

Elsevier

Access to resources Recommend Favorite

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)

By Kontoghiorghes G.J.   Pattichi K.   Hadjigavriel M.   Kolnagou A.  

Transfusion Science, Vol. 23, Iss. 3, 2000-12 ,pp. : 211-223

Elsevier

Access to resources Recommend Favorite

Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major

By Goel Himanshu   Girisha K. M.   Phadke Shubha R.  

Hematology, Vol. 13, Iss. 2, 2008-04 ,pp. : 77-82

Maney Publishing

Access to resources Recommend Favorite